Peer-influenced content. Sources you trust. No registration required. This is HCN.

Journal of Clinical OncologyPretreatment Lymphocyte Count Predicts Benefit From Concurrent Chemotherapy with Radiotherapy in Oropharyngeal Cancer

Predictive biomarkers are needed to identify patients with oropharyngeal squamous cell carcinoma (OPSCC) that could enjoy treatment de-escalation, with the attendant reduction in incidence of acute and late toxicities. In an observational study of consecutive patients with patients with oropharyngeal squamous cell carcinoma, pretreatment absolute lymphocyte count was predictive for 5-year overall survival. It also predicted benefit from the use of concurrent cisplatin chemotherapy.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form